CareLit · DOI-Nachweis · Pneumologie
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR)
DOI 10.1055/s-0036-1572212
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Rittmeyer, A Spira, K Park, J Mazieres, J Vansteenkiste, M Ballinger, D Waterkamp, M Kowanetz, L Fehrenbacher
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: In a Phase Ia clinical trial, atezolizumab (anti-PDL1) showed single-agent activity in NSCLC patients (pts) with the objective response rate (ORR) associated with PD-L1 expression on tumor-infiltrating immune cells (IC) and/or tumor cells (TC). Here we report results from the first randomized study comparing atezolizumab vs. docetaxel (doc) in unselected NSCLC pts with subgroup analyses by PD-L1-expressi…
Zitieren
Zitierempfehlung
A Rittmeyer, A Spira, K Park, J Mazieres, J Vansteenkiste, M Ballinger, D Waterkamp, M Kowanetz, L Fehrenbacher (2016) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs. docetaxel in patients with advanced NSCLC (POPLAR). Pneumologie (02). https://doi.org/10.1055/s-0036-1572212
Mit CareLit weiterarbeiten